Siponimod
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Siponimod. Siponimod is a sphingosine-1-phosphate receptor modulator, It acts on SIP1 and SIP5 receptors. Fully referenced neurology checklist.
Pharmacology
- Siponimod is a sphingosine-1-phosphate receptor modulator
- It acts on SIP1 and SIP5 receptors
Indications
Locked: subscribe to see this section.
Dose
Locked: subscribe to see this section.
Benefits
Locked: subscribe to see this section.
Complications
Locked: subscribe to see this section.
Acronym
Locked: subscribe to see this section.
References
- Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics 2017; 14:859-873.
- Subei AM, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs 2015; 29:565-575.
- Kappos L, Li DK, Stüve O, et al. Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD study. JAMA Neurol 2016; 73:1089-1098.
- Kappos L, Bar-Or A, Cree BAC, et al; EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 2018; 391:1263-1273.
- O'Sullivan C, Schubart A, Mir AK, Dev KK. The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures. J Neuroinflammation 2016; 13:31.
- And 6 more. Subscribe to see the full list
